Acurx Pharmaceuticals, Inc. (ACXP)
Automate Your Wheel Strategy on ACXP
With Tiblio's Option Bot, you can configure your own wheel strategy including ACXP - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ACXP
- Rev/Share 0.0
- Book/Share 0.1153
- PB 0.0034
- Debt/Equity 0.0
- CurrentRatio 0.0019
- ROIC 0.0065
- MktCap 9080335.0
- FreeCF/Share -0.4676
- PFCF -0.969
- PE -0.6526
- Debt/Assets 0.0
- DivYield 0
- ROE -0.0205
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 5
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Acurx Pharmaceuticals, Inc. (ACXP) Q1 2025 Earnings Call Transcript
Published: May 13, 2025 by: Seeking Alpha
Sentiment: Neutral
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP ) Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ET Company Participants Robert Shawah - Co-Founder and CFO David Luci - President and CEO Conference Call Participants Joanne Lee - Maxim Group James Molloy - Alliance Global Partners Operator Greetings and welcome to the Acurx Pharmaceuticals First Quarter 2025 Financial Results and Business Update. At this time, all participants are in a listen-only mode.
Read More
Acurx Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 13, 2025 Conference Call and Provide Business Update
Published: April 30, 2025 by: PRNewsWire
Sentiment: Neutral
STATEN ISLAND, N.Y. , April 30, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its first quarter 2025 financial results on Tuesday, May 13, 2025 at 8:00 am ET before the U.S. financial markets open.
Read More
Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase
Published: April 28, 2025 by: PRNewsWire
Sentiment: Neutral
STATEN ISLAND, N.Y. , April 28, 2025 /PRNewswire/ -- Acurx Pharmaceuticals (Nasdaq: ACXP) (Acurx or the Company), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections today announced that David P.
Read More
Acurx Pharmaceuticals (ACXP) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Published: April 08, 2025 by: Zacks Investment Research
Sentiment: Positive
After losing some value lately, a hammer chart pattern has been formed for Acurx Pharmaceuticals (ACXP), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Read More
Acurx Pharmaceuticals (ACXP) Upgraded to Buy: Here's What You Should Know
Published: March 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Acurx Pharmaceuticals (ACXP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
Acurx Pharmaceuticals, Inc. (ACXP) Q4 2024 Earnings Call Transcript
Published: March 18, 2025 by: Seeking Alpha
Sentiment: Neutral
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP ) Q4 2024 Earnings Conference Call March 18, 2025 8:00 AM ET Company Participants Robert Shawah - Co-Founder and Chief Financial Officer David Luci - President and Chief Executive Officer Conference Call Participants Thomas Yip - H.C. Wainwright James Molloy - Alliance Global Partners Claire Acheson - Independent Investment Research Operator Greetings and welcome to the Acurx Pharmaceuticals Fourth Quarter and Full Year 2024 Financial Results and Business Update.
Read More
Acurx Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative Potential of Ibezapolstat in the Treatment of CDI
Published: February 24, 2025 by: PRNewsWire
Sentiment: Neutral
Major finding provides mechanistic explanation for ibezapolstat's (IBZ) selectivity in that the predicted bactericidal interaction between IBZ and its target DNA pol IIIC is conserved across most of the Bacillota phylum, including C. difficile, while certain beneficial taxa are naturally resistant to IBZ, allowing regrowth of resistant microbes known to confer health benefits This study used in silico methods to better interpret the narrower than expected ibezapolstat (IBZ) spectrum of activity observed in human trials, which included increased proportion of certain key gut microbiota of the Bacillota phylum IBZ susceptibility of human commensal (nonpathogenic) microbiota was predicted using genomic analysis …
Read More
JPO Grants Acurx Pharmaceuticals Patent in Japan for DNA Polymerase IIIC Inhibitors
Published: February 19, 2025 by: PRNewsWire
Sentiment: Neutral
STATEN ISLAND, N.Y. , Feb. 19, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections, today announced that a new patent has been granted by the Japanese Patent Office (JPO) in January 2025.
Read More
About Acurx Pharmaceuticals, Inc. (ACXP)
- IPO Date 2021-06-25
- Website https://www.acurxpharma.com
- Industry Biotechnology
- CEO Mr. David P. Luci CPA, Esq., J.D.
- Employees 4